

# Methodology on Return on Investment: A Case Study

Jasleen Arneja and Dr. Nirmal Kandel

### **ACKNOWLEDGEMENTS**

Dr. Nirmal Kandel

Dr. Rajesh Sreedharan

Dr. Stella Chungong

Christelle Guillot

Chastine Sebolino

Odd Hansen


Dr. Amira Elasra

Parajuli Thakur

Dr. Mamunur Malik

Dr. Jamshaid Ahmed





Background

1

### **OBJECTIVES**

- Review of available literature on return on investment analyses of health interventions, including, but not limited to early warning systems
- Conduct a return on investment analysis to quantify the benefits of early warning alert and response systems, using data from one country as a case study example

### LITERATURE REVIEW

- Goal: To learn about:
  - (1) Return on investment (ROI) methods
  - (2) Early warning alert and response systems (EWARS)
- Findings from the literature on ROI and EWARS
- Over 50 documents reviewed (journal articles, textbook chapters, WHO guidelines, epi bulletins, proposals etc.)

### **EARLY WARNING ALERT AND RESPONSE SYSTEMS (EWARS)**


- Grounded in the principles of surveillance; rely on epidemic intelligence
- Purpose: collect information on epidemic prone diseases to trigger prompt public health response.
- Larger window of opportunity for rapid response and control measures → preventing the spread of potential cases
   → averting a potential outbreak
- Establishment and operationalization costs

### **ECONOMIC EVALUATION METHODS: COST BENEFIT ANALYSIS**

- ROI analyses examine the amount of benefits produced in response to a particular investment.
- Used by various industries, increasingly being used by the health sector to provide evidence of benefits from investing in certain interventions
- Cost Benefit Analysis (CBA) allows us to make comparisons by expressing the results of an intervention in terms of a benefit-cost ratio

### **EXPLORING MEASURES: DALYS, INCIDENCE, MORTALITY**

- Several indicators available to estimate disease burden
  - **Incidence:** number of new cases of disease
  - Mortality: number of deaths from a disease
  - DALYs: (Disability Adjusted Life Years): sum of the Years of Life Lost (YLL) due to premature mortality in the population and the Years Lost due to Disability (YLD) for people living with the health condition or its consequences



Methodology

2

### **AVERTED BURDEN OF DISEASE**

- 6 diseases were chosen from the over 20 monitored
- Regression modelling for attributable fraction
- Median age of death estimated based on literature review to calculate years of life lost

### **COST ESTIMATES**

- EWARS cost (establishment and investment) - from WHO Regional Office
- From the literature:
  - Country-specific average income per capita
  - Hospital and drug costs
  - Disease-specific length of hospital stay

### **LOGIC MODEL**

### **EWARS**

### **INPUT**

### **PROCESS**

### **OUTPUT**

### **OUTCOME**


### **IMPACT**

Funding, software, hardware, workspaces, staff Training,
developing
guidelines,
setting up sites
for detection of
cases and
generation of
alerts

Trained staff, developed guidelines, established sites

Alerts generated, cases detected, investigation & appropriate response generated Reduced morbidity and mortality

### CASE STUDY: PAKISTAN'S DISEASE EARLY WARNING SYSTEM (2006 to 2014)



- PAKISTAN: chosen based on convenience sampling, country suggested by EMRO
- In response to Pakistan's disastrous earthquake in 2005, the WHO and the National Institute of Health in Pakistan collaborated to develop the Disease Early Warning System (DEWS), with the objective of investigating and mitigating disease outbreaks
- DEWS ran from 2006 to 2014, with data available before establishment, during and after it ended

### **DISEASES INCLUDED IN DEWS**

**Acute Diarrhoea (non-cholera)** 

Acute Flaccid Paralysis Acute Jaundice Syndrome

**Acute Lower Respiratory Infection** 

**Acute Upper Respiratory Infection** 

Acute Viral Hepatitis Acute Watery Diarrhoea Bloody Diarrhoea

Cutaneous Leishmaniasis Dengue fever Diphtheria

Pertussis

Haemorrhagic Fever

Malaria

Measles

**Meningococcal Meningitis** 

Neonatal Tetanus

Pneumonia

Scabies

**Unexplained Fever** 

### **DISEASES INCLUDED IN OUR ANALYSIS**





**MALARIA** 



**DIARRHEA** 

Acute Diarrhoea (non-cholera) Acute Watery Diarrhoea (Suspected Cholera) Bloody Diarrhoea



LOWER RESPIRATORY INFECTION



**MENINGITIS** 

Meningococcal Meningitis



**HEPATITIS** 

### **DATA SOURCES**

- Data on establishment and operational costs of EWARS
  - WHO Pakistan Country Office
  - WHO Eastern Mediterranean Regional Office
- Data on cases (mortality rates) and covariates
  - Institute of Health Metrics and Evaluation (IHME) Global Burden of Disease (GBD) database
  - http://ghdx.healthdata.org/gbd-results-tool

### STATISTICAL ANALYSIS: ATTRIBUTABLE FRACTION



## HOW MUCH OF THE DECREASE IN MORTALITY IS ASSOCIATED WITH EWARS?

Mortality is complex, with several causal factors

Conducted inferential statistical analysis (regression modelling) to determine the proportion of the decrease in mortality attributable to EWARS, controlling for other variables.

### STATISTICAL ANALYSIS: IDEAL SCENARIO

- Panel data methods with a large dataset
- Region-specific mortality data for all included diseases matched with where and when EWARS was established
- Use variation in timing of EWARS (exogenous) to identify effects of EWARS

### STATISTICAL ANALYSIS: REAL WORLD CONSTRAINTS

- Region-specific mortality data for all diseases not available
- Region-specific EWARS establishment timelines not available
- Not enough data for panel data or time-series regression methods






### STATISTICAL ANALYSIS: ALTERNATIVE APPROACH

- Linear regression models using available aggregate data
- LIMITATIONS: Violating OLS assumptions
  - Presence of Autocorrelation
  - Non-random sample
- Generated robust variance estimates to help address these limitations





Results

1

### **REGRESSION RESULTS**



×

### **MALARIA**

Coefficient = **-8.38**, p=0.008 95%CI (-14.25, -2.51)





### LOWER RESPIRATORY INFECTION

95%CI (-1.41, -0.36)

Coefficient = -0.88, p=0.003



### **MENINGITIS**

Coefficient = **-0.73**, p=0.008 95%CI (-1.24, -0.22)



### **DIARRHEA**

Coefficient = **-2.85** p=0.024 95%CI (-5.27, -0.43)



### **HEPATITIS**

EWARS NOT ASSOCIATED WITH STATISTICALLY SIGNIFICANT REDUCTION IN HEPATITIS MORTALITY RATES

**ANALYSES WERE CONDUCTED USING STATA/IC 15** 







### THE AVERTED MORTALITY ASSOCIATED WITH EWARS

	EWARS MORTALITY RATE REDUCTION	DEATHS AVERTED	YEARS OF LIFE LOST AVERTED (PER DEATH)	YEARS OF LIFE LOST AVERTED
MENINGITIS	-0.7318823	1014	40.83	41395
MEASLES	-8.378174	11606	63.83	740793
DIARRHEA	-2.846807	3943	66.08	260586
LOWER RESPIRATORY INFECTIONS	-0.8820816	1222	34.83	42558

### **INVESTMENT COSTS OF EWARS (MILLIONS OF RUPEES) - FROM EMRO**

ITEM	COST
ESTABLISHMENT	12.09
TRAINING, CAPACITY BUILDING	10.24
DEWS TOOLS, NEWSLETTERS, EDUCATIONAL MATERIAL	3.12
EQUIPMENT, FURNITURE, MAINTENANCE	2.35
LAB ITEMS AND MEDICATIONS	1.50
TRANSPORT AND MAINTENANCE	6.90

ITEM	COST
BUILDING CONSTRUCTION	9.20
PRINTING,OFFICE SUPPLIES AND PUBLICATIONS	0.30
SUPERVISION, MONITORING, FIELD VISITS, OUTBREAK INVESTIGATION	1.00
MID-TERM EVALUATION	0.20
OTHER COSTS	0.30
TOTAL COSTS	47.20

### **OPERATIONAL COSTS OF EWARS (MILLIONS OF RUPEES) - FROM EMRO**

ITEM	соѕт
ESTABLISHMENT	3.10
TRAINING, CAPACITY BUILDING	1.00
DEWS TOOLS, NEWSLETTERS, EDUCATIONAL MATERIAL	0.55
POL & MAINTENANCE OF TRANSPORT	0.25
SUPERVISION, MONITORING, FIELD VISITS, OUTBREAK INVESTIGATION	0.20
UTILITIES & MAINTENANCE	0.20

ITEM	COST
PRINTING,OFFICE SUPPLIES AND PUBLICATIONS	0.15
CONTINGENT EXPENDITURE	0.05
OTHER COSTS (POSTAGE, OFFICE EXPENDITURE)	0.05
TOTAL COSTS	5.55

ANNUAL OPERATION COST = 5.55 MILLION
YEARS IN OPERATION = 8 i.e. 2006 to 2014
TOTAL OPERATIONAL COST = 44.4 MILLION



### **ADJUSTING FOR INFLATION**

Estimated cost of EWARS:

INVESTMENT 47.20 million PKR
OPERATION 44.44 million PKR

- Cost in USD: INVESTMENT 405928.6 USD OPERATION 381840 USD
- Inflation factor 13.7 (median, 2010), based on literature review
- Cost of EWARS, adjusted for inflation:

461540.8 + 434152.1 **= 895,692.9 USD** 

	PKR	USD INFLATION ADJUSTED (USD)	
INVESTMENT	47201000	405928.6	461540.82
ANNUAL OPERATION	5550000	47730	54269.01
ALL YEARS OPERATION	44400000	381840	434152.08
TOTAL INVESTM	ENT + OPERAT	ION COST	895692.90



### **CALCULATING THE BENEFITS (AVERTED LOSSES, USD)**

#### **CASE MANAGEMENT**

	WAGE LOSS AVERTED	HOSPITAL COSTS	DRUG COSTS	TOTAL COSTS AVERTED
MENINGITIS	62629989	383734	152074	62094181
MEASLES	1120820150	4392766	1740858	1114686526
DIARRHEA	394266402	1492611	591524	392182267
LOWER RESPIRATORY INFECTIONS	64390819	462485	183283	63745051
TOTAL	1642107360	6731595	2667739	1,632,708,025

### **CALCULATING THE BENEFIT COST RATIO**

$$BCR = \frac{Benefits}{Costs}$$

$$BCR = \frac{Wage\ Loss\ Averted - (Hospital\ Costs + Drug\ Costs)}{(Investment\ Costs + Operational\ Costs)}$$


**Total Benefits = 1,632,708,025 USD** 

**Total Costs = 895,693 USD** 

**BCR = 1822.84** 

Positive return on investment!!!





### Conclusion





# THANK YOU!